MX2023002539A - Methods of treating pde iv-mediated diseases or conditions. - Google Patents

Methods of treating pde iv-mediated diseases or conditions.

Info

Publication number
MX2023002539A
MX2023002539A MX2023002539A MX2023002539A MX2023002539A MX 2023002539 A MX2023002539 A MX 2023002539A MX 2023002539 A MX2023002539 A MX 2023002539A MX 2023002539 A MX2023002539 A MX 2023002539A MX 2023002539 A MX2023002539 A MX 2023002539A
Authority
MX
Mexico
Prior art keywords
conditions
mediated diseases
methods
pde
treating
Prior art date
Application number
MX2023002539A
Other languages
Spanish (es)
Inventor
Vuk Koprivica
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of MX2023002539A publication Critical patent/MX2023002539A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

The disclosure provides methods and compositions for the treatment of PDE IV-mediated diseases or conditions, including inflammatory diseases or conditions, using a compound of Formula (I) or a pharmaceutically acceptable salt thereof:.
MX2023002539A 2020-09-10 2021-09-10 Methods of treating pde iv-mediated diseases or conditions. MX2023002539A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063076774P 2020-09-10 2020-09-10
PCT/US2021/049870 WO2022056265A1 (en) 2020-09-10 2021-09-10 Methods of treating pde iv-mediated diseases or conditions

Publications (1)

Publication Number Publication Date
MX2023002539A true MX2023002539A (en) 2023-03-14

Family

ID=78080507

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002539A MX2023002539A (en) 2020-09-10 2021-09-10 Methods of treating pde iv-mediated diseases or conditions.

Country Status (12)

Country Link
US (1) US20230364100A1 (en)
EP (1) EP4210674A1 (en)
JP (1) JP2023541261A (en)
KR (1) KR20230066350A (en)
CN (1) CN116507336A (en)
AU (1) AU2021338837A1 (en)
BR (1) BR112023004214A2 (en)
CA (1) CA3191177A1 (en)
CL (1) CL2023000648A1 (en)
IL (1) IL300628A (en)
MX (1) MX2023002539A (en)
WO (1) WO2022056265A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503108A (en) 2002-09-16 2006-01-26 グラクソ　グループ　リミテッド Pyrazolo [3,4-b] pyridine compounds and their use as phosphodiesterase inhibitors
PT3394040T (en) 2015-12-24 2022-03-24 Univ California Cftr regulators and methods of use thereof
AU2018321926B2 (en) * 2017-08-24 2023-09-21 The Regents Of The University Of California Ocular pharmaceutical compositions

Also Published As

Publication number Publication date
IL300628A (en) 2023-04-01
CL2023000648A1 (en) 2023-10-13
CN116507336A (en) 2023-07-28
JP2023541261A (en) 2023-09-29
US20230364100A1 (en) 2023-11-16
KR20230066350A (en) 2023-05-15
WO2022056265A1 (en) 2022-03-17
CA3191177A1 (en) 2022-03-17
BR112023004214A2 (en) 2023-04-11
AU2021338837A1 (en) 2023-04-06
EP4210674A1 (en) 2023-07-19

Similar Documents

Publication Publication Date Title
MX2023001689A (en) Bcl-2 INHIBITORS.
MX2020009372A (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones.
GEP20237561B (en) Protein tyrosine phosphatase inhibitors
MX2023001876A (en) Rapamycin derivatives.
MX2022010011A (en) Novel prmt5 inhibitors.
MX2022000244A (en) PYRROLO [2, 3-b] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF.
MX2023007192A (en) Prmts inhibitors.
MX2020007947A (en) Erbb/btk inhibitors.
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
MX2021015854A (en) Compounds for treating cns disorders.
MX2021011606A (en) Compounds targeting prmt5.
MX2019009653A (en) Piperidine-substituted mnk inhibitors and methods related thereto.
MX2021010122A (en) Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders.
EA202192900A1 (en) MODULATORS OF INTEGRATED STRESS RESPONSE PATHWAYS
MX2021015056A (en) Pyrrolopyrimidine compound and use thereof.
MX2021007247A (en) Rapamycin derivatives.
MX2021012105A (en) Pyrrole compounds.
MX2022000390A (en) Macrocyclic spirocycle derivatives as mcl-1 inhibitors.
MX2019006612A (en) IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS.
ZA202300912B (en) Tyk-2 inhibitor
MX2020002630A (en) IMIDAZO[1,5-A]PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS.
PH12019502652A1 (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
ZA202106519B (en) Caspase inhibitors and methods of use thereof
MX2022002446A (en) Perk inhibiting pyrrolopyrimidine compounds.
JOP20210319A1 (en) Pyrrolidine compounds